Publications

Dissertation (2010): 

“Huntington disease: Hypothalamic, endocrine and metabolic aspects”

My dissertation can also be downloaded in parts here.

 

Publications:

  1. Aziz NA, Swaab DF, Pijl H, Roos RA. (2007). Hypothalamic dysfunction and neuroendocrine and metabolic alterations in Huntington’s disease: clinical consequences and therapeutic implications. Rev Neurosci.18(3-4):223-251. (review)
  2. Roos RA, Aziz NA (2007). Hypocretin-1 and secondary signs in Huntington’s disease. Parkinsonism Rel Disorders. 13: 387-390. (original article)
  3. Aziz NA, Aziz MI. (2007). Losing weight by defecating at night. Medical Hypotheses. 67(4): 989. (letter)
  4. Aziz NA, Fronczek R, Maat-Schieman MA, Unmehopa U, Roelandse F, Overeem S, van Duinen S, Lammers GJ, Swaab DF, Roos RA. (2008). Hypocretin and Melanin-Concentrating Hormone in Patients with Huntington Disease. Brain Pathol. 18(4): 474-483. (original article)
  5. Aziz NA, Van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, EHDI Study Group; Roos RA (2008). Weight loss in Huntington’s disease increases with higher CAG repeat number. Neurology.71(19): 1506-1513. (original article)
  6. Aziz NA, Van der Marck MA, Olde Rikkert MGM, Pijl H, Bloem BR, Roos RA (2008). “Gewichtsverlies bij neurodegeneratieve aandoeningen.”. Tijdschr Neurol Neurochir. 109;5:192-9. (Dutch, review)
  7. Aziz NA, Van Belzen MJ, Roos RA (2008). Intergenerational CAG repeat instability is highly heritable in Huntington’s disease. J Med Genet. 45: 766. (letter)
  8. Aziz NA, Van der Marck MA, Olde Rikkert MGM, Pijl H, Bloem BR, Roos RA (2008). Weight loss in neurodegenerative disorders. J Neurol. 255(12):1872-80. (review)
  9. Aziz NA, Roos RA (2009). Huntington CAG repeat size does not modify onset age in familial Parkinson’s disease: The GenePD study. Mov Disord. 24(8):1253. (letter)
  10. Aziz NA, Pijl H, Frölich M, Van der Graaf AW, Roelfsema F, Roos RA (2009). Increased activity of the hypothalamic-pituitary-adrenal axis in early-stage Huntington’s disease patients. J Clinical Endocrinol Metab. 94(4):1223-8. (original article)
  11. Aziz NA, Van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, Roos RA (2009). Weight loss in Huntington’s disease increases with higher CAG repeat number. Neurology. 73(7): 572. (letter)
  12. Aziz NA, Roelfsema F, Frölich M, Roos RA, Pijl H (2009). A strategy for finding the optimal deconvolution estimates for hormone secretory kinetics using AutoDecon. Anal. Biochem. 391(1):69-71 (original article)
  13. Aziz NA, Pijl H, Frölich M, Van der Graaf AW, Roelfsema F, Roos RA (2009). Leptin secretion rate increases with higher CAG repeat number in Huntington’s disease patients. Clin Endocrinol (Oxf).73(2): 206-11. (original article)
  14. Aziz NA, Pijl H, Frölich M, Schröder-van der Elst JP, van der Bent C, Roelfsema F, Roos RA. Delayed onset of the diurnal melatonin rise in patients with Huntington’s disease (2009). J Neurol. 256:1961–1965. (original article)
  15. Aziz NA, Jurgens CK, Landwehrmeyer GB on behalf of the EHDN Registry Study Group, Van Roon-Mom WM, Van Ommen GJ, Stijnen T, Roos RA (2009). Normal and mutant HTT interact to affect clinical severity and progression in Huntington’s disease. Neurology. 73(16): 1280-5. (original article)
  16. Aziz NA, Pijl H, Frölich M, Schröder-van der Elst JP, van der Bent C, Roelfsema F, Roos RA (2010). Growth hormone and ghrelin secretion are associated with clinical severity in Huntington’s disease. Eur J Neurol. 17(2): 280-8. (original article)
  17. Aziz NA, Anguelova GV, Marinus J, Van Dijk JG, Roos RA (2010). Autonomic symptoms in patients and premanifest mutation carriers of Huntington’s disease. Eur J Neurol. 17(8): 1068-74. (original article)
  18. Aziz NA, Pijl H, Frölich M, Snel M, Streefland T, Roelfsema F, Roos RA. Systemic energy homeostasis in Huntington’s disease patients. J Neurol Neurosurg Psychiatry. 81(11):1233-7. (original article)
  19. Aziz NA, Anguelova GV, Marinus J, Lammers GJ, Roos RA (2010). Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington’s disease. Parkinsonism Rel Disorders. 16(5): 345-50. (original article)
  20. Aziz NA, Pijl H, Frölich M, Roelfsema F, Roos RA. Altered thyrotropic and lactotropic axes regulation in Huntington’s disease (2010). Clin Endocrinol (Oxf). 73(4): 540-5. (original article)
  21. Aziz NA, Van der Burg JM, Roos RA. High insulinlike growth factor I is associated with cognitive decline in Huntington disease (2011). Neurology. 76(7): 675-6. (letter)
  22. Aziz NA, Pijl H, Frölich M, Roelfsema F, Roos RA (2011). Leptin, adiponectin and resistin secretion and diurnal rhythmicity are unaltered in Parkinson’s disease. Movement Disorders. 26(4): 760-1. (original article)
  23. Van Wamelen DJ, Shan L, Aziz NA, Anink JA, Bao AM, Roos RA, Swaab DF (2010). Functional increase of brain histaminergic signalling in Huntington’s disease. Brain Pathol. 21(4): 419-27. (original article)
  24. Donjacour CE, Aziz NA, Frölich M, Roelfsema F, Overeem S, Lammers GJ, Pijl H. Sodium oxybate increases prolactin secretion in narcolepsy patients and healthy controls (2011). Eur J Endocrinol. 164(3): 363-70. (original article)
  25. Donjacour CE, Aziz NA, Frölich M, Roelfsema F, Overeem S, Lammers GJ, Pijl H (2011). The effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls. Am J Physiol Endocrinol Metab. 300(6): E1069-75. (original article)
  26. Aziz NA, Van Belzen MJ, Coops ID, Belfroid RD, Roos RA (2011). Parent-of-Origin Differences of Mutant HTT CAG Repeat Instability in Huntington’s disease. Eur J Med Genet. 54(4): 413-8. (original article)
  27. Aziz NA, Pijl H, Frölich M, Roelfsema F, Roos RA (2011). Diurnal secretion profiles of growth hormone, thyrotropin and prolactin in Parkinson’s disease. J Neuroendocrinol. 23(6): 519-24. (original article)
  28. Van der Burg JM, Winqvist A, Aziz NA, Maat-Schieman ML, Roos RA, Bates GP, Brundin P, Björkqvist M, Wierup N (2011). Gastrointestinal dysfunction contributes to weight loss in Huntington’s disease mice. Neurobiol. Dis. 44(1): 1-8. (original article)
  29. Aziz NA, Pijl H, Roos RA. Weight loss in obese older adults (2011). N Engl J Med. 364(25): 2467. (letter)
  30. Aziz NA, Van Roon-Mom WM, Roos RA (2011). CAG repeat size in the normal HTT allele and age of onset in Huntington’s disease. Movement Disorders 26(13):2450-1. (letter)
  31. Donjacour CE, Pardi D, Aziz NA, Frölich M, Roelfsema F, Overeem S, Pijl H, Lammers GJ (2011). Ghrelin and leptin levels in human narcolepsy and in response to sodium oxybate. J Clin Sleep Med.9(8):797-803.(original article)
  32. Van Wamelen DJ, Aziz NA, Anink JA, Roos RA, Swaab DF (2012). Paraventricular Nucleus Neuropeptide Expression in Huntington’s disease Patients. Brain Pathol. 22(5), 654-661. (original article)
  33. Van Wamelen DJ, Aziz NA, Anink JA, Roos RA, Swaab DF (2012). Neuropeptide Alterations in the Infundibular Nucleus of Huntington’s disease Patients. J.Neuroendocrinol. 25(2):198-205. (original article)
  34. Van Wamelen DJ, Aziz NA, Anink JA, Steenhoven R, Roos RA, Swaab DF (2013). The suprachiasmatic nucleus is severely affected in Huntington’s disease patients. Sleep. 36(1): 117-125. (original article)
  35. Donjacour CE, Kalsbeek A, Overeem S, Lammers GJ, Bothorel B, Pijl H, Aziz NA (2012). Altered circadian rhythm of melatonin concentrations in hypocretin deficient men. Chronobiol Int. 29(3):356-62. (original article)
  36. Aziz NA, Roos RA, Gusella JF, Lee JM, Macdonald ME (2012). CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion. Neurology. 79(9):952. (letter)
  37. Aziz NA, Roos RA (2013). Weight loss in Huntington’s disease: characteristics, pathophysiology and clinical management. Neurodegenerative Disease Management. 3(3): 253-266. (original article)
  38. Donjacour CE, Pardi D, Aziz NA, Frölich M, Roelfsema F, Overeem S, Pijl H, Lammers GJ (2013). Plasma Total Ghrelin and Leptin Levels in Human Narcolepsy and Matched Healthy Controls: Basal Concentrations and Response to Sodium Oxybate. Journal of Clinical Sleep Medicine. 15;9(8):797-803. (original article)
  39. Aziz NA, Roos RA (2013). Characteristics, pathophysiology and clinical management of weight loss in Huntington’s disease. Neurodegenerative Disease Management. 3(3): 253-266. (review)
  40. Van Wamelen DJ, Aziz NA, Zhao J, Balesar R, Unmehopa U, Anink JA, Roos RA, Swaab DF (2013). Decreased hypothalamic prohormone convertase expression in Huntington’s disease patients. J Neuropathol Exp Neurol. 72(12):1126-34. (original article)
  41. Aziz NA, Rozing MP (2013). Profit (p) index: the degree to which authors benefit from co-authors. Plos ONE. 8(4): e59814. (original article) This article was included in the book “The best idea of 2013” (ISBN: 978-90-79051-09-0) and kickstarted a national discussion on the use (and misuse of) bibliometic indices, including coverage by NRC Handelsblad (27-28 april 2013; 2 November 2013; 16 November 2013).
  42. Van Wamelen DJ, Aziz NA, Roos RA, Swaab DF (2014). Hypothalamic alterations in Huntington’s disease patients: comparison with genetic rodent models. J.Neuroendocrinol. 26(11):761-75. (review)
  43. Donjacour CE, Aziz NA,Overeem S, Kalsbeek A, Pijl H, Lammers GJ (2014). Glucose and fat metabolism in narcolepsy and the effect of sodium oxybate: a hyperinsulinemic-euglycemic clamp study. Sleep. 37(4):795-801. (original article)
  44. Tannemaat MR, Aziz NA (2015). The prevalence of ‘Clinical Neurophysiology’ and related terms in the English literature: A specialty in transition. Clin. Neurophysiol. 126(8): 1459-61. (editorial)
  45. Aziz NA, Tannemaat MR (2015). A microscope for subtle movements in clinical neurology. Neurology. 85(10):920. (Video NeuroImage)
  46. Van der Burg JM, Pijl H, Campman YJ, Roos RA, Aziz NA (2015). Does midlife obesity really lower dementia risk? Lancet Diabetes & Endocrinology 3(7):499-500. (letter)
  47. Aziz NA, Peeters-Scholte CM, de Bruine FT, Klumper FJ, Adama van Scheltema PN, Lopriore E, Steggerda SJ (2016). Fetal cerebellar hemorrhage, three cases with follow-up. Ultrasound Obstet Gynecol. 47(6): 785-6. (original article)
  48. Aziz NA, Onkenhout W, Kerstens HJ, Roos RA (2015). Cystathionine Levels in Patients With Huntington Disease (2015). Plos Curr. 16(7). (original article)
  49. Van Wamelen DJ, Roos RA, Aziz NA (2015). Managing sleep and circadian rhythm disturbances in Huntington disease (2015). Neurodegenerative Disease Management. 5(6): 549-59. (review)
  50. Tannemaat MR, Aziz NA (2017). Creating dynamic virtual quarantines using “Pokémon Go” to limit infectious diseases spread. Medical Hypotheses. 99: 76-7. (letter)
  51. Blauw LL*, Aziz NA*, Tannemaat MR, Blauw CA, De Craen AJ, Pijl H, Rensen PC (2017). Diabetes incidence and glucose intolerance prevalence increase with higher outdoor temperature. BMJ Open Diabetes Research & Care. 5: e000317. *Joint first-author (This article received wide international media coverage, including CNN, LA Times, Huffington Post, ‘De Standaard’ and ‘Nederlands Dagblad’). (original article)
  52. Stuitje GA, Van Belzen MJ, Gardiner SL, Van Roon-Mom WM, Boogaard MW, REGISTRY Investigators of the European Huntington Disease Network, Tabrizi SJ, Roos RA, Aziz NA (2017). Age of onset in Huntington disease is influenced by CAG repeat variations in other polyglutamine disease-associated genes. Brain. 140(7):e42. doi: 10.1093/brain/awx122. (research letter)
  53. Gardiner SL, Van Belzen MJ, Boogaard MW; Van Roon-Mom WM, Rozing MP, Van Hemert AM, Smit JH, Beekman AT, Van Grootheest G, Schoevers RA, Oude Voshaar RC, Comijs HC, Penninx BW, Van der Mast RC, Roos RA, Aziz NA (2017). Large normal-range TBP and ATXN7 CAG repeat lengths are associated with increased lifetime risk of depression. Translational Psychiatry. 7(6): e1143. doi: 10.1038/tp.2017.116. (original article)
  54. Aziz NA (2017). Transfer entropy as a tool for inferring causality from observational studies in epidemiology. bioRxiv https://doi.org/10.1101/149625 (original article, preprint)
  55. Gardiner SL, Van Belzen MJ, Boogaard MW; Van Roon-Mom WM, Rozing MP, Van Hemert AM, Smit JH, Beekman AT, Van Grootheest G, Schoevers RA, Oude Voshaar RC, Roos RA, Comijs HC, Penninx BW, Van der Mast RC, Aziz NA (2017). Huntingtin gene repeat size variations affect risk of lifetime depression. Translational Psychiatry. 7(12): e1143. (original article)
  56. Van der Burg JM, Gardiner SL, Ludolph AC, Landwehrmeyer GB, Roos RA, Aziz NA (2017). Body weight is a robust predictor of clinical progression in Huntington disease. Annals of Neurology. 82(3):479-483. (original article)
  57. Aziz MH, Sideras K, Aziz NA, Haen R, Roos D, Saida L, Suker M, van der Harst E, Mieog JS, Bonsing BA, Klaver Y, Groot Koerkamp B, van Eijck CH (2017). The systemic immune-inflammation index independently predicts survival and recurrence in resectable pancreatic cancer and its prognostic value depends on bilirubin levels. Annals of Surgery (accepted) (original article)
  58. Keo A, Aziz NA, Dzyubachyk O, Van der Grond J, Roon-Mom WM, Lelieveldt BF, Reinders MJ, Mahfouz A (2017). Co-expression patterns between ATN1 and ATXN2 coincide with brain regions affected in Huntington’s disease. Frontiers in Molecular Neuroscience.10:399. (original article)
  59. Aziz NA, Balint B (2017). The missing link in polyglutamine disorders. Movement Disorders Clinical Practice. 5(1): 29-30. (letter)
  60. Aziz NA, Van der Burg JM, Tabrizi SJ, Landwehrmeyer GB. Overlap between age of onset and progression determinants in Huntington disease. Neurology: 90(24): 2099-2106 (original article) (Editorial about this article: Neurology: 90 (24):1087-88).
  61. Gardiner SL, de Mutsert R, Trompet S, Boogaard MW, Van Dijk KW, Jukema JW, Slagboom PE, Roos RA, Pijl H, Rosendaal FR, Aziz NA (2018). Repeat length variations in polyglutamine disease-associated genes affect body mass index. International Journal of Obesity (accepted) (original article)
  62. Gardiner SL, Milanese C, Boogaard MW, Buijsen RA, Hogenboom M, Roos RA, Mastroberardino PG, Van Roon-Mom WM, Aziz NA (2018). Bioenergetic status in fibroblast cell lines are associated with age of onset in Huntington disease. Neurology: Genetics: 4; 4(5):e275. (original article)
  63. Aziz NA, Weydt P (2018). Telomere length as a modifier of age-at-onset in Huntington disease: A two-sample Mendelian randomization study. Journal of Neurology (accepted) (research letter)
  64. Rozing MP, Van Leeuwen TN, Reitsma PH, Rosendaal FR, Aziz NA (2019). Freeloading in Biomedical Research. Scientometrics (Epub ahead of print) doi: 10.1007/s11192-018-2984-3 (original article)
  65. Gardiner SL, Harder AV, Campman YJ, Trompet S, Gussekloo J, Van Belzen MJ, Boogaard MW, Roos RA, Jansen IE, Pijnenburg YA, Scheltens Ph, Van der Flier WM, Aziz NA (2019). Repeat length variations in polyglutamine disease-associated genes modify disease expression in Alzheimer disease. Neurobiol Aging;73:230.e9-17.
  66. Reilmann R, McGarry A, Grachev ID, Savola JM, Borowsky B, Eyal E, Gross N, Langbehn D, Schubert R, Wickenberg AT, Papapetropoulos S, Hayden M, Squitieri F, Kieburtz K, Landwehrmeyer GB; European Huntington’s Disease Network; Huntington Study Group investigators (2019). Safety and efficacy of pridopidine in patients with Huntington’s disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study. Lancet Neurology; 18(2):165-176. (Aziz NA part of the Investigator Group)
  67. Aziz NA. Statin use and delayed onset of Huntington’s disease (2019). Movement Disorders (accepted) (letter)
  68. Anderson DG, Ferreira-Correia A, Rodrigues FB, Aziz NA, Carr J, Wild EJ, Margolis RL, Krause A (2019). Comparison of the Huntington’s disease-like 2 and Huntington’s disease clinical phenotypes. Movement Disorders Clinical Practice (accepted) (original article)
  69. Aziz NA. Evaluating depression and suicidality in tetrabenazine users with Huntington disease (2019). Neurology (accepted) (letter)
  70. Gardiner SL, Boogaard MW, Trompet S, de Mutsert R, Rosendaal FR, Gussekloo J, Jukema JW, Roos RA, Aziz NA (2019). High prevalence of carriers of intermediate and pathological polyglutamine disease-associated alleles in large population-based cohorts. JAMA Neurol. (accepted) (original article)

Book chapters

  1. Aziz NA, Vogel J (2005). “Reactieprocessen, aandacht en energetiek”. In: Cognitie, of hoe het brein werkt: 81-93. Leiden University, Leiden, The Netherlands. (in Dutch)
  2. Nijs S, Aziz NA (2005). “Een instinct voor taal?”. In: Cognitie, of hoe het brein werkt: 107-118. Leiden University, Leiden, The Netherlands. (in Dutch)
  3. Aziz NA, Van der Burg JM, Pijl H, Roos RA (2009). Huntington’s disease and metabolic abnormalities: lessons from mice and men. In: Treatment Strategies – EASD 2009 Review: 32-39. The Cambridge Research Centre Ltd, United Kingdom.
  4. Aziz NA, Roos RA (2010). Autonomic symptoms in Huntington’s disease – current understanding and perspectives for the future. European Neurological Review. 5(2): 46-8.
  5. Van der Burg JM, Aziz NA, Björkqvist M (2014). Peripheral pathology in Huntington’s disease. In: Huntington’s disease (4th edition). Editors: G. Bates, S. Tabrizi & Lesley Jones. Oxford University Press, New York.

 

Other publications

 JOURNAL WATCH

  1. Aziz NA. Journal Watch/Article Review of “Tabrizi SJ et al. Lancet Neurol. 12(7), 637-649 (2013).” Neurodegenerative Disease Management. 3(5): 2.
  2. Aziz NA, Roos RA. Journal Watch/Article Review of “Wenning GK et al. Lancet Neurol. 12(3), 264-274 (2013).” Neurodegenerative Disease Management. 3(5): 2.
  3. Aziz NA, Roos RA. Journal Watch/Article Review of “Doody RS et al. N Engl J Med, 369(4): 341-350 (2013).” Neurodegenerative Disease Management. 
  4. Aziz NA, Roos RA. Journal Watch/Article Review of “Van der Marck MA et al. Lancet NeurolNeurodegenerative Disease Management. 

 E-LETTERS

  1. Aziz NA, Tannemaat MR (2015). Scary movies and venous thrombosis: Google’s answer. (http://www.bmj.com/content/351/bmj.h6367/rr-1)
  2. Tannemaat MR, Aziz NA (2016). Will “Low Sugar” Overtake “Low Fat” in Popularity as a New Year’s Resolution This Year? (http://www.bmj.com/content/351/bmj.h4962/rr-41)